Status:
UNKNOWN
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Collaborating Sponsors:
Physicians, Innovations, Science for Children Fund
Conditions:
Acute Myeloid Leukemia, Childhood
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE3
Brief Summary
Minimal-residual disease (MRD) will be measured either by flow cytometry, or polymerase chain reaction (PCR) methods, in 3 check-points and it will be one of the decision-making control parameter for ...
Detailed Description
Genetic alterations in acute myeloid leukemia (AML) clone are well known prognostic risk factors of AML relapse. Standard risk group includes favorable t (15;17) (q22; q21) and inv (16)/t (16;16). Hig...
Eligibility Criteria
Inclusion
- de novo acute myeloid leukemia
- signed informed consent
Exclusion
- diagnosis of: Fanconi anemia, acute promyelocytic leukemia, MDS, JMML, AML as secondary malignancy, Dawn syndrome.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03846362
Start Date
April 1 2019
End Date
January 1 2025
Last Update
March 16 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Regional Children's Clinical Hospital № 1
Yekaterinburg, Sverdlovsk Oblast, Russia, 620149
2
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
Moscow, Russia, 117198